Critical care

[키워드] 30-Day mortality Administered administration adverse event adverse events analysed Biomarker C-reactive protein clinical Clinical improvement cohorts of patient comparable complementary Complementary therapies coronavirus disease COVID-19 Critical Critical care decrease Efficacy epidemiologically group hospitalised Hypothesis inflammatory parameters knowledge lactate dehydrogenase medication Mortality onset of symptom outcome Patient patients with COVID-19 pharmacological treatment Pneumonia Primary outcome pulmonary medicine Quotient radiological radiological improvement Radiology. randomised controlled trial reductions in SaO_{2} secondary Severe COVID-19 pneumonia statistically significant difference subgroup subgroups the timing therapy Tocilizumab tocilizumab administration two group were recorded while
[DOI] 10.1136/ejhpharm-2020-002669 PMC 바로가기